MarketCapExport financials
Pieris Pharmaceuticals (PIRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Pieris Pharmaceuticals Balance Sheet 2025-2011 | PIRS
Brief balance sheet overview of Pieris Pharmaceuticals
The comparison uses five available annual reports from the 2021–2025 interval.
Assets fell from $153.6 million to $59.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities grew more slowly than assets: -69.3% versus -61.2%. Expansion relied more on equity, improving funding quality.
The share of internal funding stands at 47% versus 33.1% initially, providing a reasonable foundation.
The period ended with net cash: net debt stood at -$57.3 million. This supports financial flexibility.
Cash represents 97.4% of assets versus 76.7% initially, showing how the immediate liquidity reserve changed.
Retained earnings are negative at -$135.4 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Pieris Pharmaceuticals's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Pieris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-57.3 M | - | - | -25.5 M | -103 M | -70.4 M | -46 M | -74.9 M | -37.9 M | -29.4 M | -29.3 M | -10.7 K | -4.73 K | - | - |
Long Term Debt |
431 K | - | - | 12.2 M | 13.8 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
202 K | - | - | 859 K | 1.05 M | 1.03 M | 733 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
20.2 M | 13.6 M | 9.07 M | 31 M | 52.2 M | 6 K | 62.7 M | 53.3 M | 46.6 M | 1.46 M | 23.9 K | 334 K | 4.92 M | - | - |
Total Current Liabilities |
11.3 M | 12 M | 2.36 M | 36.6 M | 50.6 M | 22.1 M | 27 M | 48.1 M | 45.8 M | 8.38 M | 2.8 M | 3.52 M | 1.77 M | - | - |
Total Liabilities |
31.6 M | 25.6 M | 11.4 M | 67.6 M | 103 M | 74 M | 89.7 M | 101 M | 92.4 M | 9.84 M | 2.82 M | 3.85 M | 6.69 M | - | - |
Deferred Revenue |
- | - | - | 20.8 M | 25.1 M | 12.6 M | 11.3 M | 35.6 M | 37.2 M | 2.27 M | - | - | 545 K | - | - |
Retained Earnings |
-135 M | -93.7 M | -76.3 M | -290 M | -257 M | - | -174 M | -147 M | -120 M | -103 M | -79.9 M | -65.8 M | -56 M | - | - |
Total Assets |
59.6 M | 88.2 M | 7.55 M | 95.5 M | 154 M | 105 M | 141 M | 141 M | 104 M | 35.1 M | 34 M | 21.9 M | 7.28 M | - | - |
Cash and Cash Equivalents |
58 M | 83.6 M | 7.35 M | 38.6 M | 118 M | 70.4 M | 62.3 M | 74.9 M | 37.9 M | 29.4 M | 29.3 M | 18.5 M | 3.69 M | - | - |
Book Value |
28 M | 62.6 M | -3.88 M | 27.9 M | 50.8 M | 31 M | 51.4 M | 39.9 M | 11.5 M | 25.2 M | 31.1 M | 18 M | 585 K | - | - |
Total Shareholders Equity |
28 M | 62.6 M | -74.5 M | -93.8 M | 50.8 M | 31 M | 51.4 M | 39.9 M | 11.5 M | 25.2 M | 31.1 M | 18 M | 585 K | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Pieris Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
260 K | 318 K | 375 K | 431 K | - | - | - | - | - | - | - | - | - | 11.9 M | - | 12.2 M | 11.4 M | 12.3 M | 13.4 M | 13.8 M | 14.4 M | 15 M | 15 M | 15.9 M | 15.4 M | 15 M | 14.9 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
26.6 M | 24.7 M | 22.3 M | 20.2 M | 17.9 M | 16.4 M | 14.9 M | 13.6 M | - | - | - | 9.07 M | - | 12.7 M | - | 31 M | 29.9 M | 34.4 M | 44.2 M | 52.2 M | 60.6 M | 64.4 M | 47.3 M | 51.8 M | 52.3 M | 52.9 M | 53.5 M | 62.7 M | 56.3 M | 70.4 M | 59.8 M | 53.3 M | 60.8 M | 54.4 M | 67.8 M | 46.6 M | 55.3 M | 60.8 M | 32.4 M | 1.46 M | - | 2.74 M | 3.53 M | 23.9 K | 308 K | - | 296 K | 334 K | - | 4.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
41.5 M | 36.6 M | 31.4 M | 31.6 M | 28.3 M | 26 M | 23.9 M | 25.6 M | - | - | - | 11.4 M | 28.9 M | 47 M | - | 67.6 M | 63.4 M | 69.9 M | 83.7 M | 103 M | 110 M | 108 M | 77.6 M | 74 M | 72 M | 71.1 M | 74 M | 89.7 M | 96.1 M | 111 M | 101 M | 101 M | 101 M | 107 M | 123 M | 92.4 M | 94.3 M | 96.6 M | 43.8 M | 9.84 M | 9.84 M | 9.16 M | 10 M | 2.82 M | 2.55 M | 2.82 M | 2.55 M | 3.85 M | 3.88 M | 6.69 M | 3.88 M | 6.69 M | 474 | 3.32 K | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 994 K | 17.7 M | - | 20.8 M | 18.5 M | 22.9 M | 20.9 M | 25.1 M | 26.4 M | 25.5 M | 17.2 M | 12.6 M | 10 M | 7.91 M | 10 M | 11.3 M | 27.2 M | 28.4 M | 28.2 M | 35.6 M | 31.9 M | 44.6 M | 46.3 M | 37.2 M | 31.3 M | 24.8 M | 5.17 M | 2.28 M | 2.27 M | 2.46 M | 2.46 M | - | - | - | - | - | - | 545 K | - | 545 K | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-198 M | -173 M | -151 M | -135 M | -123 M | -111 M | -102 M | -93.7 M | -326 M | -323 M | -320 M | -76.3 M | -310 M | -300 M | - | -290 M | -282 M | -273 M | -262 M | -257 M | -248 M | -231 M | -216 M | -211 M | -197 M | -183 M | -178 M | -174 M | -173 M | -171 M | -159 M | -147 M | -135 M | -129 M | -129 M | -120 M | -128 M | -121 M | -111 M | -103 M | -103 M | -89.9 M | -84 M | -79.9 M | -77 M | -79.9 M | -69.5 M | -65.8 M | -65.8 M | -56 M | -65.8 M | -56 M | -274 | -8.23 K | - | - | - | - | - | - | - | - | - |
Total Assets |
239 M | 254 M | 264 M | 59.6 M | 66.9 M | 73.7 M | 79.4 M | 88.2 M | 20.5 M | 25.1 M | 29.5 M | 7.55 M | 59.4 M | 87.5 M | - | 95.5 M | 99.2 M | 114 M | 137 M | 154 M | 164 M | 155 M | 116 M | 105 M | 116 M | 118 M | 124 M | 141 M | 117 M | 131 M | 131 M | 141 M | 152 M | 162 M | 173 M | 104 M | 98.9 M | 106 M | 61.9 M | 35.1 M | 35.1 M | 46.5 M | 37.2 M | 34 M | 36.2 M | 34 M | 16.8 M | 21.9 M | 21.9 M | 7.28 M | 21.9 M | 7.28 M | 5.2 K | 90 | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
193 M | 188 M | 206 M | 58 M | 63.6 M | 70.4 M | 75.6 M | 83.6 M | 19.4 M | 19.7 M | 19.1 M | 7.35 M | 32.9 M | 44.9 M | - | 38.6 M | 48.4 M | 54.3 M | 83.7 M | 118 M | 125 M | 119 M | 66.8 M | 70.4 M | 66.9 M | 44.3 M | 47.4 M | 62.3 M | 46.1 M | 54.9 M | 52.1 M | 74.9 M | 89.5 M | 50.6 M | 110 M | 37.9 M | 89.9 M | 50.3 M | 55.2 M | 29.4 M | 29.4 M | 40.4 M | 31.2 M | 29.3 M | 32.3 M | 29.3 M | 13.2 M | 18.5 M | 18.5 M | 3.69 M | 18.5 M | 3.69 M | 90 | 90 | - | 6.33 M | - | - | - | - | - | - | - |
Book Value |
198 M | 217 M | 232 M | 28 M | 38.7 M | 47.8 M | 55.6 M | 62.6 M | 20.5 M | 25.1 M | - | -3.88 M | 30.5 M | 40.5 M | - | 27.9 M | 35.8 M | 44.4 M | 53.4 M | 50.8 M | 53.9 M | 46.7 M | 38.2 M | 31 M | 43.7 M | 46.7 M | 49.8 M | 51.4 M | 20.6 M | 19.5 M | 30.2 M | 39.9 M | 50.3 M | 55.3 M | 50.7 M | 11.5 M | 4.56 M | 9.33 M | 18 M | 25.2 M | 25.2 M | 37.3 M | 27.2 M | 31.1 M | 33.7 M | 31.1 M | 14.2 M | 18 M | 18 M | 585 K | 18 M | 585 K | 4.73 K | -3.23 K | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
198 M | 217 M | 232 M | 28 M | 38.7 M | 47.8 M | 55.6 M | 62.6 M | -87.4 M | -80.8 M | -76.9 M | -74.5 M | 30.5 M | 40.5 M | 15.5 M | -93.8 M | 35.8 M | 44.4 M | 53.4 M | 50.8 M | 53.9 M | 46.7 M | 38.2 M | 31 M | 43.7 M | 46.7 M | 49.8 M | 51.4 M | 20.6 M | 19.5 M | 30.2 M | 39.9 M | 50.3 M | 55.3 M | 50.7 M | 11.5 M | 4.56 M | 9.33 M | 18 M | 25.2 M | 25.2 M | 37.3 M | 27.2 M | 31.1 M | 33.7 M | 31.1 M | 14.2 M | 18 M | 18 M | -3.23 K | 18 M | 585 K | 4.73 K | 4.73 K | - | 496 K | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Pieris Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Israel
USA
China
Canada
Russia
Niderland
Spain
Germany